During the last session, Relmada Therapeutics Inc (NASDAQ:RLMD)’s traded shares were 0.67 million, with the beta value of the company hitting 0.38. The 52-week high for the RLMD share is $5.09, that puts it down -1596.67 from that peak though still a striking 20.0% gain since the share price plummeted to a 52-week low of $0.24. The company’s market capitalization is $8.95M, and the average intraday trading volume over the past 10 days was 0.38 million shares, and the average trade volume was 1.09 million shares over the past three months.
Relmada Therapeutics Inc (RLMD) received a consensus recommendation of Sell from analysts. That translates to a mean rating of 3.00. RLMD has a Sell rating from 1 analyst(s) out of 1 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 0 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be 0.
Relmada Therapeutics Inc (NASDAQ:RLMD) trade information
Relmada Therapeutics Inc (RLMD) registered a -0.44% downside in the last session and has traded in the green over the past 5 sessions. The stock plummet -0.44% in intraday trading to $0.30, hitting a weekly high. The stock’s 5-day price performance is 0.14%, and it has moved by 7.54% in 30 days. Based on these gigs, the overall price performance for the year is -93.67%. The short interest in Relmada Therapeutics Inc (NASDAQ:RLMD) is 1.49 million shares and it means that shorts have 3.02 day(s) to cover.
The consensus price target of analysts on Wall Street is $7, which implies an increase of 95.71% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $2 and $8 respectively. As a result, RLMD is trading at a discount of -2566.67% off the target high and -566.67% off the low.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 0.68%. While earnings are projected to return 64.15% in 2025, the next five years will return 35.23% per annum.
RLMD Dividends
Relmada Therapeutics Inc is due to release its next quarterly earnings on 2025-Mar-26. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Relmada Therapeutics Inc (NASDAQ:RLMD)’s Major holders
Relmada Therapeutics Inc insiders own 8.04% of total outstanding shares while institutional holders control 29.84%, with the float percentage being 32.45%. DEEP TRACK CAPITAL, LP is the largest shareholder of the company, while 66.0 institutions own stock in it. As of 2024-06-30, the company held over 1.23 million shares (or 16.3686% of all shares), a total value of $3.7 million in shares.
The next largest institutional holding, with 1.2 million shares, is of VESTAL POINT CAPITAL, LP’s that is approximately 15.9076% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $3.6 million.
Also, the Mutual Funds coming in first place with the largest holdings of Relmada Therapeutics Inc (RLMD) shares are VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and Franklin Strategic Series-FRANKLIN BIOTECHNOLOGY DISCOVERY FUND . Data provided on Dec 31, 2024 indicates that VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund owns about 851.92 shares. This amounts to just over 8.61 percent of the company’s overall shares, with a $0.25 million market value. The same data shows that the other fund manager holds slightly less at 456.4, or about 4.61% of the stock, which is worth about $0.14 million.
